Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Repositori Obert UdL
Publication Artículo científico (JournalArticle)

Single-nucleus RNA sequencing identifies a novel tenogenic heterologous differentiation in endometrial carcinosarcomas: implications for diagnosis and tumor classification

  • González Martínez, Silvia
  • Palacios, José
  • Carretero Barrio, Irene
  • Fernández Lanza, Val
  • Cortés Salgado, Alfonso
  • Román, Javier
  • Matias-Guiu, Xavier
  • Gatius Calderó, Sònia
  • Cortés, Javier
  • Pérez Mies, Belén
Carcinosarcomas (CSs) are aggressive biphasic tumors characterized by epithelial and mesenchymal components, whose histogenesis and differentiation dynamics remain poorly understood. We present single-nucleus RNA sequencing (snRNA-seq) analysis of six CSs (five endometrial and one ovarian) and two normal endometrial samples, profiling over 96,298 cells. By integrating transcriptomic data with inferred copy number variations (CNVs), immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and in situ hybridization (ISH) validation, we resolved the complex cellular architecture of these tumors, identified lineage-specific programs, and revealed unexpected differentiation trajectories. snRNA-seq was used to further refine the histopathological classification of three cases by uncovering heterologous differentiation not previously recognized: one rhabdomyogenic, one osteogenic, and, notably, one exhibiting a novel tenogenic program, defined by the expression of SCX, MKX, and TNMD. All CSs displayed a prominent mesenchymal compartment comprising both undifferentiated fibroblast-like cells and distinct lineage committed populations, including rhabdomyoblasts (Rhab), tenoblasts (Teno), osteoblasts (Osteo), and chondroblasts (Chond). In some tumors, multiple mesenchymal identities co-existed, and in others, differentiation gradients (e.g. immature versus mature rhabdomyoblasts) were observed. These patterns underscore the cellular plasticity and multilineage potential of the sarcomatous component. Furthermore, the expression of specialized interface markers (COL22A1, NCAM1, ACAN, CHRNG, MUSK) suggests that some tumors use structured developmental programs reminiscent of the muscle-tendon junction, enthesis, or neuromuscular junction. CNV analysis revealed tumor-specific genomic alterations with clonal and subclonal patterns linked to differentiation state, which were validated by FISH. Altogether, this study demonstrates that CSs are not static biphasic tumors but rather complex ecosystems with extensive developmental plasticity. Our findings redefine their classification and support the use of single-nucleus approaches to uncover hidden differentiation trajectories in highly heterogeneous cancers, including the discovery of a previously unreported tenogenic lineage. Our results challenge the diagnosis of homologous CS when only morphological criteria are applied. © 2026 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland., We wish to thank María Luisa Zamorano, Ana Belén Sánchez, and Marta Rosas for their excellent technical assistance. Additionally, we want to particularly acknowledge the patients and the BioBank Hospital Ramón y Cajal-IRYCIS (B.0000678), integrated in the Biobanks and Biomodels Platform of the ISCIII, for its collaboration. The research was supported by grants from the Instituto de Salud Carlos III (PI25/01933, PI22/01892, PMP22/00054, PMP21/00107), ‘A way to achieve Europe’ (FEDER), and ‘Contigo contra el cáncer de la mujer’ Foundation.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Costs of biomarker testing in advanced non-small cell lung cancer: a global study comparing next-generation sequencing and single-gene testing

  • Malapelle, Umberto
  • Chen, Chien-Chin
  • Álava, Enrique de
  • Hofman, Paul
  • Kazdal, Daniel
  • Kim, Tae-Jung
  • Lim, Tony Kiat Hon
  • Ryška, Aleš
  • Saetta, Angelica A.
  • Schuuring, Ed
  • Troncone, Giancarlo
  • Biscuola, Michele
  • Chen, Yi-Lin
  • Tan, Gek San
  • Marquette, Charles Hugo
  • Michelli, Maria
  • Ter Elst, Arja
  • Vošmiková, Hana
  • Kapp, Joshua
  • Gonzalez-McQuire, Sebastian
  • Giannopoulou, Andromachi
  • Franzini, Jean Marie
  • Aramburu, Victoria Lucia Rabsiun
  • Baggi, Anna
  • Stenzinger, Albrecht
Qualified researchers may request data from Amgen. Complete details are available at: http://www.amgen.com/datasharing., Current European/US guidelines recommend that molecular testing in advanced non-small cell lung cancer (aNSCLC) be performed using next-generation sequencing (NGS). However, the global uptake of NGS is limited, largely owing to reimbursement constraints. We compared real-world costs of NGS and single-gene testing (SGT) in nonsquamous aNSCLC. This observational study was conducted across 10 pathology centers in 10 different countries worldwide. Biomarker data collected via structured questionnaires (1 January-31 December 2021) were used to feed micro-costing analyses for three scenarios ['Starting Point' (SP; 2021-2022), 'Current Practice' (CP; 2023-2024), and 'Future Horizons' (FH; 2025-2028)] in both a real-world model, comprising all biomarkers tested by each center, and a standardized model, comprising the same sets of biomarkers across centers. Testing costs (including retesting) encompassed personnel costs, consumables, equipment, and overheads. Overall, 4,491 patients with aNSCLC were evaluated. Mean per-patient costs decreased for NGS relative to SGT over time, with real-world model costs 18% lower for NGS than for SGT in the SP scenario, and 26% lower for NGS than for SGT in the CP scenario. Mean per-biomarker costs also decreased over time for NGS relative to SGT. In the standardized model, the tipping point for the minimum number of biomarkers required for NGS to result in cost savings (per patient) was 10 and 12 in the SP and CP scenarios, respectively. Retesting had a negligible impact on cost analyses, and results were robust to variation in cost parameters. This study provides robust real-world global evidence for cost savings with NGS-based panels over SGT to evaluate predictive biomarkers in nonsquamous aNSCLC when the number of biomarkers to be tested exceeds 10. Widespread adoption of NGS may enable more efficient use of limited healthcare resources., We thank all investigators involved in the study. Medical writing support, including development of a draft outline and subsequent drafts in consultation with the authors, collating author comments, copyediting, fact checking, and referencing, was provided by Frances Thompson, PhD, of Aspire Scientific Limited (Bollington, UK). Funding for medical writing support for this article was provided by Amgen (Europe) GmbH (Rotkreuz, Switzerland). Data collection in this study was funded by Amgen (Europe), Rotkreuz, Switzerland. Data collection was also supported by the Ministry of Science of Spain-NextGen (PMP21/00107 INGENIO)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Single-nucleus RNA sequencing identifies a novel tenogenic heterologous differentiation in endometrial carcinosarcomas: implications for diagnosis and tumor classification

  • González Martínez, Silvia
  • Palacios, José
  • Carretero Barrio, Irene
  • Fernández Lanza, Val
  • Cortés Salgado, Alfonso
  • Román, Javier
  • Matias-Guiu, Xavier
  • Gatius Calderó, Sònia
  • Cortés, Javier
  • Pérez Mies, Belén
Carcinosarcomas (CSs) are aggressive biphasic tumors characterized by epithelial and mesenchymal components, whose histogenesis and differentiation dynamics remain poorly understood. We present single-nucleus RNA sequencing (snRNA-seq) analysis of six CSs (five endometrial and one ovarian) and two normal endometrial samples, profiling over 96,298 cells. By integrating transcriptomic data with inferred copy number variations (CNVs), immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and in situ hybridization (ISH) validation, we resolved the complex cellular architecture of these tumors, identified lineage-specific programs, and revealed unexpected differentiation trajectories. snRNA-seq was used to further refine the histopathological classification of three cases by uncovering heterologous differentiation not previously recognized: one rhabdomyogenic, one osteogenic, and, notably, one exhibiting a novel tenogenic program, defined by the expression of SCX, MKX, and TNMD. All CSs displayed a prominent mesenchymal compartment comprising both undifferentiated fibroblast-like cells and distinct lineage committed populations, including rhabdomyoblasts (Rhab), tenoblasts (Teno), osteoblasts (Osteo), and chondroblasts (Chond). In some tumors, multiple mesenchymal identities co-existed, and in others, differentiation gradients (e.g. immature versus mature rhabdomyoblasts) were observed. These patterns underscore the cellular plasticity and multilineage potential of the sarcomatous component. Furthermore, the expression of specialized interface markers (COL22A1, NCAM1, ACAN, CHRNG, MUSK) suggests that some tumors use structured developmental programs reminiscent of the muscle-tendon junction, enthesis, or neuromuscular junction. CNV analysis revealed tumor-specific genomic alterations with clonal and subclonal patterns linked to differentiation state, which were validated by FISH. Altogether, this study demonstrates that CSs are not static biphasic tumors but rather complex ecosystems with extensive developmental plasticity. Our findings redefine their classification and support the use of single-nucleus approaches to uncover hidden differentiation trajectories in highly heterogeneous cancers, including the discovery of a previously unreported tenogenic lineage. Our results challenge the diagnosis of homologous CS when only morphological criteria are applied. © 2026 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland., We wish to thank María Luisa Zamorano, Ana Belén Sánchez, and Marta Rosas for their excellent technical assistance. Additionally, we want to particularly acknowledge the patients and the BioBank Hospital Ramón y Cajal-IRYCIS (B.0000678), integrated in the Biobanks and Biomodels Platform of the ISCIII, for its collaboration. The research was supported by grants from the Instituto de Salud Carlos III (PI25/01933, PI22/01892, PMP22/00054, PMP21/00107), ‘A way to achieve Europe’ (FEDER), and ‘Contigo contra el cáncer de la mujer’ Foundation.